Travere Therapeutics Inc (TVTX) Stock Price, Quote & News

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 969 7879

Website: www.travere.com

Address:

3611 Valley Centre Drive, Suite 300, San Diego, United States

DeadInvestor Aug. 6 at 8:26 PM

$TVTX $114.4m revs. $0.14 / share loss on the quarter. Blew away estimates. Up $1.02 after hours right now. Doesn’t seem to be enough. At this rate, TVTX will easily have over a $1.00 earnings next year. That equates to a 15 P/E . And just getting started. Wow.

0 · Reply

DeadInvestor Aug. 6 at 4:54 PM

$TVTX Any predictions on revenues? We should hear in 3 hrs or so. Average analyst estimates is at $100M. Tall order in my view. Hoping I’m completely wrong.

1 · Reply

DeadInvestor Aug. 5 at 3:52 PM

$TVTX If TVTX were to get bought out, who are the likely acquirers and why?

0 · Reply

SalmanAziz Aug. 4 at 4:33 PM

$TVTX new to this stock. I am hearing some chatter about the FDA date for spartsentan. Do most people think this drug will be approved. IF so what price will it go to?

1 · Reply

MGeronimo Jul. 27 at 10:32 PM

$TVTX IN AT 15.32

0 · Reply

XkaliburTrading Jul. 11 at 9:14 PM

$TVTX https://www.benzinga.com/pressreleases/25/07/b46378798/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4

0 · Reply

Night_Owl_Biotech Jul. 7 at 5:54 PM

$TVTX is off ~32% from its $21.50/peak 8 weeks ago after reporting a comfortable Q1 2025 beat where the $XBI is more or less unchanged (and off ~40% from its Feb 2025 peak) TVTX now trades for 0.11X 10-year projected revenues. By comparison, as disappointed as $CALT investors were with its M&A share price, CALT was still acquired for 0.28X 10-year projected revenues. It appears Filspari's patent expires in 7/2034 (9 years from now). CALT forecast its IgA therapy to peak in year 5 (we assume due to a like patent expiration but cannot confirm). CALT's revenue forecast provided its buyer attached. In April 2025 Guggenheim published a $2.0B Filspari peak sales estimate in FSGS (PDUFA January 2026). The lowest Filspari peak sales estimate we could find in FSGS was $300MM. Obviously a CRL would be a bad thing but approval... This is not investment advice.

0 · Reply

Kier_Severed Jul. 7 at 4:41 PM

$TVTX Entering a new position here - price seems right ☺️

0 · Reply

BenTheDo Jul. 5 at 3:48 AM

$TVTX If pegtibatinase get's approved fair value is around $100 depending on market saturation.

2 · Reply

JarvisFlow Jul. 1 at 11:30 AM

HC Wainwright & Co. updates rating for Travere Therapeutics ( $TVTX ) to Buy, target set at 30.

0 · Reply

Travere Therapeutics Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:30 PM EDT - 1 day ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Jul 30, 2025, 4:30 PM EDT - 7 days ago

Travere Therapeutics to Report Second Quarter 2025 Financial Results

Jul 11, 2025, 5:00 PM EDT - 26 days ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2025, 7:01 AM EDT - 2 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Jun 10, 2025, 7:00 AM EDT - 2 months ago

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Jun 4, 2025, 10:00 AM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 4:30 PM EDT - 2 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

May 30, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

May 22, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

May 21, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach Out

May 20, 2025, 5:45 PM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect

May 20, 2025, 3:47 PM EDT - 2 months ago

Travere Therapeutics: Establishing A Position After Last Week's Selloff

May 15, 2025, 4:05 PM EDT - 2 months ago

Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS

May 1, 2025, 11:07 PM EDT - 3 months ago

Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:01 PM EDT - 3 months ago

Travere Therapeutics Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:01 AM EDT - 3 months ago

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Apr 29, 2025, 2:00 AM EDT - 3 months ago

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Apr 24, 2025, 4:30 PM EDT - 3 months ago

Travere Therapeutics to Report First Quarter 2025 Financial Results

Mar 31, 2025, 4:30 PM EDT - 4 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Mar 17, 2025, 7:01 AM EDT - 5 months ago

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

Feb 21, 2025, 8:17 AM EST - 5 months ago

Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:01 PM EST - 5 months ago

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:30 PM EST - 6 months ago

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 7:01 AM EST - 6 months ago

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Jan 6, 2025, 4:30 PM EST - 7 months ago

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:53 AM EST - 8 months ago

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dec 18, 2024, 9:39 AM EST - 8 months ago

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

Nov 25, 2024, 4:30 PM EST - 9 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences

Nov 7, 2024, 9:05 PM EST - 9 months ago

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 7, 2024, 4:01 PM EST - 9 months ago

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Oct 31, 2024, 3:13 PM EDT - 9 months ago

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

Oct 26, 2024, 7:01 AM EDT - 10 months ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Oct 21, 2024, 4:30 PM EDT - 10 months ago

Travere Therapeutics to Report Third Quarter 2024 Financial Results

DeadInvestor Aug. 6 at 8:26 PM

0 · Reply

DeadInvestor Aug. 6 at 4:54 PM

$TVTX Any predictions on revenues? We should hear in 3 hrs or so. Average analyst estimates is at $100M. Tall order in my view. Hoping I’m completely wrong.

1 · Reply

DeadInvestor Aug. 5 at 3:52 PM

$TVTX If TVTX were to get bought out, who are the likely acquirers and why?

0 · Reply

SalmanAziz Aug. 4 at 4:33 PM

$TVTX new to this stock. I am hearing some chatter about the FDA date for spartsentan. Do most people think this drug will be approved. IF so what price will it go to?

1 · Reply

MGeronimo Jul. 27 at 10:32 PM

$TVTX IN AT 15.32

0 · Reply

XkaliburTrading Jul. 11 at 9:14 PM

$TVTX https://www.benzinga.com/pressreleases/25/07/b46378798/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4

0 · Reply

Night_Owl_Biotech Jul. 7 at 5:54 PM

0 · Reply

Kier_Severed Jul. 7 at 4:41 PM

$TVTX Entering a new position here - price seems right ☺️

0 · Reply

BenTheDo Jul. 5 at 3:48 AM

$TVTX If pegtibatinase get's approved fair value is around $100 depending on market saturation.

2 · Reply

JarvisFlow Jul. 1 at 11:30 AM

HC Wainwright & Co. updates rating for Travere Therapeutics ( $TVTX ) to Buy, target set at 30.

0 · Reply

DeadInvestor Jul. 1 at 3:12 AM

$TVTX 72% of today’s volume was short. Up to 13% of float now. This thing will go up sharply if earnings surprise to the upside (which they had better).

0 · Reply

ils85 Jun. 23 at 12:21 PM

$PCSA $PTCT $TVTX $SUPN

0 · Reply

ils85 Jun. 23 at 10:42 AM

$PCSA $PCSA 🚨 All lining up: 🔹 Armistice Capital just reaffirmed their 9.99% stake (578,605 shares) in today’s 13G. 🔹 $7M offering closed—cash in hand, priced smart. 🔹 Licensing deal signed with Intact Therapeutics for their gastroparesis candidate—big market, major unmet need. 🧠 Armistice runs a $6B+ biotech-heavy book ($PTCT, $TVTX, $SUPN). They don’t guess—they position. 💡 PCSA’s now funded, partnered, and backed by smart money. The float is tiny. Any spark sends this vertical. 🚀 Catalyst season is just beginning. Don’t sleep. #biotech #undervalued #catalysts #smartmoney #lowfloat

1 · Reply

FloatTrip Jun. 23 at 1:37 AM

$TVTX Solid Bio Company. Parked some money here, and it's safe and will do well. Kinda like a savings account, except this one pays better!

0 · Reply

FloatTrip Jun. 13 at 2:51 AM

$TVTX The New FDA is slinging Adcoms to BIOS to fit their own slow starting schedules, they are lazy and not picking up the pace, where the previous FDA set motions forward. BHVN also had this done recently too, for a previously FDA fast-tracked orphan designation PDUFA...now an ADCOM meeting scheduled, just to slow the PDUFA's down, so the inept FDA can catch up on present day progress in the Pharma space.

1 · Reply

Quantumup Jun. 11 at 12:02 PM

Citi⬇️ $TVTX' to $32 from $35, reiterated at a Buy and placed the stock on a 90-Day Upside Catalyst Watch. $NVS $AHKSY $VRTX Citi said in its note, "We have updated our model to reflect 1Q25 reporting. Our target moves to $32 from $35 after adjustments to the model, with corresponding changes to EPS, reflecting $TVTX's YE24 share count vs. the prior 2024 weighted-average. The full approval of Filspari in the EU (increased POS from 85% to 100%) and updated launch timing of Filspari in FSGS based on the announced PDUFA target action date of January 13, 2026 are also reflected in our updated forecasts. We expect Travere to receive FDA approval on or before the upcoming PDUFA date of August 28, 2025 for the sNDA seeking a lighter REMS program for Filspari for the treatment of IgAN. Specifically, the potential modifications include a step-down in liver monitoring from monthly to quarterly, and in a best-case scenario the REMS could be lifted entirely. Citi went on to say:

0 · Reply

JarvisFlow Jun. 11 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Travere Therapeutics ( $TVTX ), setting the rating to Buy with a target price of 30.

0 · Reply

TurdEquities111 Jun. 4 at 7:09 PM

$TVTX I bet if next ER is amazing then this will pop again.

0 · Reply

speedrr Jun. 4 at 7:31 AM

$TVTX https://www.stocktitan.net/news/TVTX/travere-therapeutics-to-present-new-filspari-sparsentan-data-at-the-rynpgd9xznu4.html

0 · Reply

TurdEquities111 Jun. 2 at 11:26 AM

$VERA How different is this company with $TVTX?

0 · Reply

Quantumup May. 29 at 7:28 PM

Morgan Stanley reiterated $BHVN Overweight-$63 and said, "We offer our takeaways from $BHVN's R&D Day on 5/28." $TVTX NVS $AHKSY $SRRK $LLY $RYTM JAZZ IONS Morgan Stanley added, "Mgmt discussed progress across a diversified pipeline portfolio, presenting new data for degrader platform, and new modalities in oncology and neuroscience. The company is ramping commercialization efforts ahead of Troriluzole's 4Q PDUFA. $BHVN highlighted advances across the company's increasingly diversified pipeline portfolio, including in weight/muscle management (anti-myostatin), inflammation/autoimmune (degraders), neurological (ion channels), and oncology (ADCs). The company presented additional data for immunoglobulin-specific degraders BHV-1400 for IgA nephropathy and BHV-1300 IgG1/2/4 immune-mediated diseases, as well as initial set of data for antibody-drug conjugates (ADCs) for various cancer types. Morgan Stanley went on to say:

0 · Reply

Boombashka May. 28 at 8:07 PM

$TVTX why did it fall again? Was it because they lost their priority thing?

0 · Reply

Market Cap	1.42B
Revenue (ttm)	233.18M
Net Income (ttm)	-321.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-137.90%
Debt to Equity Ratio	0.00

Volume	2,225,675
Avg Vol	1,413,360
Day's Range	N/A - N/A
Shares Out	88.81M
Stochastic %K	89%
Beta	0.74
Analysts	Strong Sell
Price Target	$34.20